Testing Ivabradine On Patient Derived Xenografts: A Novel Potential Targeted Treatment For Breast Cancer
Grant Data
Project Title
Testing Ivabradine On Patient Derived Xenografts: A Novel Potential Targeted Treatment For Breast Cancer
Principal Investigator
Professor Khoo, Ui Soon
(Project Coordinator (PC))
Co-Investigator(s)
Dr Lee Kin Wah, Terence
(Co-Investigator)
Dr Tsoi Ho
(Co-Investigator)
Professor Siu David Chung Wah
(Co-Investigator)
Professor Kwong Ava
(Co-Investigator)
Dr Luk Man-yee
(Co-Investigator)
Duration
6
Start Date
2018-01-18
Completion Date
2018-07-31
Amount
126440
Conference Title
Testing Ivabradine On Patient Derived Xenografts: A Novel Potential Targeted Treatment For Breast Cancer
Keywords
Breast Cancer, Patient Derived Xenografts, Potential Targeted Treatment, Testing Ivabradine
Discipline
Others - Medicine, Dentistry and Health
HKU Project Code
InP/010/18
Grant Type
Innovation and Technology Fund Internship Programme
Funding Year
2016
Status
Completed
Objectives
Breast cancer patients who cannot benefit from targeted therapies need to be treated with chemotherapeutic agents. With limited choices of targeted therapies, new targeted drugs are needed. We have previously shown that Ivabradine, an FDA approved therapeutic HCN channel blocker used clinically to treat chronic angina, can effectively suppress breast cancer cell-line growth through induction of apoptosis, cell cycle arrest, cell senescence and autophagy. We aim to test the efficacy of Ivabradine to inhibit growth of breast cancer cells obtained from patients by using patient derived tumor xenograft (PDTX). Cancer cells will be collected from freshly excised surgical specimens and pleural fluid containing metastatic cancer. The viable cells implanted into the mammary fat pad of NOD/SCID mice will develop into PDTX tumors that will be treated with Ivabradine or placebo, administered by subcutaneous injection. Mice will be sacrificed between 1-4 months post injection, and tumors harvested. Tumor size and weight will be documented and the samples examined for proliferation, apoptosis, autophagy and senescence to determine the effect of Ivabradine on patient derived tumor xenografts. Since Ivabradine is already FDA approved, successful completion of this project paves the way for possible clinical trial as a new drug to treat breast cancer.